{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:57:45Z","timestamp":1767963465606,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Developmental & Comparative Immunology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.dci.2013.04.004","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T16:48:30Z","timestamp":1366130910000},"page":"68-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases"],"prefix":"10.1016","volume":"41","author":[{"given":"Satoko","family":"Matsueda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukazu","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Kuromatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritsuko","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Yutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Shichijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Mine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiya","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Sata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyogo","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Sasada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dci.2013.04.004_b0005","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.vaccine.2012.01.006","article-title":"CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl\/6 and BALB\/c mouse tumors","volume":"30","author":"Bequet-Romero","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.dci.2013.04.004_b0010","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.dci.2013.04.004_b0015","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1016\/j.vaccine.2011.02.017","article-title":"Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine","volume":"29","author":"Chen","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.dci.2013.04.004_b0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1086\/650462","article-title":"Association between severe pandemic 2009 influenza A (H1N1) virus. Infection and immunoglobulin G(2) subclass deficiency","volume":"50","author":"Gordon","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.dci.2013.04.004_b0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/pros.10280","article-title":"Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients","volume":"57","author":"Harada","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.dci.2013.04.004_b0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.dci.2013.04.004_b0035","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/01.cji.0000161394.11831.3f","article-title":"Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor","volume":"28","author":"Hu","year":"2005","journal-title":"J. Immunother."},{"key":"10.1016\/j.dci.2013.04.004_b0040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ijc.1461","article-title":"Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases","volume":"94","author":"Imai","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.dci.2013.04.004_b0045","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0022-5347(05)65821-1","article-title":"Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide","volume":"166","author":"Inoue","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.dci.2013.04.004_b0050","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1349-7006.2003.tb01493.x","article-title":"Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients","volume":"94","author":"Kobayashi","year":"2003","journal-title":"Cancer Sci."},{"key":"10.1016\/j.dci.2013.04.004_b0055","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/00365510410007008","article-title":"New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization","volume":"64","author":"Komatsu","year":"2004","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.dci.2013.04.004_b0060","first-page":"97","article-title":"A correlation between symptom severity and unbalanced reactive IgA production in Japanese cedar pollinosis patients","volume":"26","author":"Komatsu","year":"2008","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.dci.2013.04.004_b0065","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1158\/1078-0432.CCR-05-0682","article-title":"Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles","volume":"11","author":"Matsueda","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.dci.2013.04.004_b0070","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.dci.2013.04.004_b0075","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00262-006-0216-9","article-title":"Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles","volume":"56","author":"Minami","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.dci.2013.04.004_b0080","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1158\/1078-0432.CCR-1117-3","article-title":"Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses","volume":"10","author":"Mine","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.dci.2013.04.004_b0085","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00262-010-0822-4","article-title":"A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer","volume":"59","author":"Noguchi","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.dci.2013.04.004_b0090","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/pros.21261","article-title":"A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer","volume":"71","author":"Noguchi","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.dci.2013.04.004_b0095","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.4161\/cbt.10.12.13448","article-title":"Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination","volume":"10","author":"Noguchi","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.dci.2013.04.004_b0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/pros.20078","article-title":"Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients","volume":"60","author":"Ogata","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.dci.2013.04.004_b0105","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbrc.2006.12.232","article-title":"HCV core protein immunization with Montanide\/CpG elicits strong Th1\/Th2 and long-lived CTL responses","volume":"354","author":"Roohvand","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.dci.2013.04.004_b0110","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.dci.2013.04.004_b0115","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.ejca.2004.04.003","article-title":"Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients","volume":"40","author":"Shomura","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.dci.2013.04.004_b0120","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2010.29.7499","article-title":"Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen \u2013 A24 with recurrent or progressive glioblastoma multiforme","volume":"29","author":"Terasaki","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.dci.2013.04.004_b0125","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1349-7006.2012.02202.x","article-title":"Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer","volume":"103","author":"Terazaki","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.dci.2013.04.004_b0130","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.1158\/1078-0432.CCR-09-1537","article-title":"Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients","volume":"15","author":"Toh","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.dci.2013.04.004_b0135","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.dci.2013.04.004_b0140","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1158\/1078-0432.CCR-05-0559","article-title":"Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma","volume":"11","author":"Yajima","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.dci.2013.04.004_b0145","first-page":"6459","article-title":"Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes","volume":"61","author":"Yamada","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.dci.2013.04.004_b0150","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjc.6601960","article-title":"Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients","volume":"91","author":"Yao","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.dci.2013.04.004_b0155","doi-asserted-by":"crossref","first-page":"16723","DOI":"10.1073\/pnas.1110814108","article-title":"Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab","volume":"108","author":"Yuan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.dci.2013.04.004_b0160","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1158\/0008-5472.CAN-08-2476","article-title":"Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan","volume":"69","author":"Zeng","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.dci.2013.04.004_b0165","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/erm.10.12","article-title":"Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors","volume":"10","author":"Zhang","year":"2010","journal-title":"Expert Rev. Mol. Diagn."}],"container-title":["Developmental & Comparative Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145305X13000931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145305X13000931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:33:03Z","timestamp":1758936783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145305X13000931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0145305X13000931"],"URL":"https:\/\/doi.org\/10.1016\/j.dci.2013.04.004","relation":{},"ISSN":["0145-305X"],"issn-type":[{"value":"0145-305X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases","name":"articletitle","label":"Article Title"},{"value":"Developmental & Comparative Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dci.2013.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}